Literature DB >> 2003979

Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.

M C Etienne1, S Bernard, J L Fischel, P Formento, J Gioanni, J Santini, F Demard, M Schneider, G Milano.   

Abstract

Folinic acid (FA) and cisplatin (CDDP) both potentiate the cytotoxicity of 5-fluorouracil (5-FU). The activity of various drug combinations including 5-FU, CDDP and FA was tested on two human cell lines derived from squamous cell carcinomas of the head and neck. Cytotoxicity was assessed by the semi-automated colorimetric MTT test. The drugs were tested in clinically achievable conditions (concentrations and duration of exposure). The dose response curves for 5-FU (0-100 ng ml-1) associated with FA (10(-7)-10(-5) M) reflected a progressive increase in 5-FU cytotoxicity with increasing FA concentrations. When CDDP (0-5 micrograms ml-1) was associated with 5-FU, CDDP-mediated enhancement of 5-FU cytotoxicity was apparent only when CDDP was given before 5-FU. The triple association CDDP, 5-FU and FA was also tested. In this case, for an identical final cytotoxicity, the presence of FA (10(-6) M) permitted reduction of the 5-FU concentration between 24.2 and 42% and reduction of the CDDP concentration between 13.8 and 72.7%. These observations may be beneficial for the design of more rational therapeutic trials associating CDDP, 5-FU and FA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2003979      PMCID: PMC1971844          DOI: 10.1038/bjc.1991.88

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

2.  Curability of mouse L1210 leukemia by combination of 5-fluorouracil, cis-diamminedichloroplatinum(II), and low doses of gamma-rays.

Authors:  C Dionet; P Verrelle
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

3.  Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.

Authors:  P C Amrein; S A Weitzman
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

4.  The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts.

Authors:  J A Houghton; C Schmidt; P J Houghton
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

5.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

Authors:  D Machover; E Goldschmidt; P Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; J L Misset; L Schwarzenberg; J B Fourtillan
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

6.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.

Authors:  J Kish; A Drelichman; J Jacobs; J Hoschner; J Kinzie; J Loh; A Weaver; M Al-Sarraf
Journal:  Cancer Treat Rep       Date:  1982-03

8.  Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.

Authors:  K Keyomarsi; R G Moran
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

Review 9.  5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?

Authors:  D J Kerr
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

10.  Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.

Authors:  A Thyss; M Schneider; J Santini; C Caldani; J Vallicioni; P Chauvel; F Demard
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

View more
  10 in total

1.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

Authors:  W Scheithauer; H Rosen; G V Kornek; C Sebesta; D Depisch
Journal:  BMJ       Date:  1993-03-20

Review 2.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck.

Authors:  P G Sacks
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

Review 3.  Chemotherapy of oesophago-gastric cancer.

Authors:  P J Ross; S Rao; D Cunningham
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 4.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.

Authors:  K Aubry; J L Labourey; J P Bessède; N Tubiana-Mathieu; M Rigaud
Journal:  Clin Med Oncol       Date:  2008-01-22

6.  Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].

Authors:  H P Knaebel; A Märten; J Schmidt; K Hoffmann; C Seiler; K Lindel; H Schmitz-Winnenthal; S Fritz; T Herrmann; H Goldschmidt; R Krempien; U Mansmann; J Debus; V Diehl; M W Büchler
Journal:  BMC Cancer       Date:  2005-04-12       Impact factor: 4.430

7.  A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.

Authors:  M C Etienne; X Pivot; J L Formento; R J Bensadoun; P Formento; O Dassonville; M Francoual; G Poissonnet; X Fontana; M Schneider; F Demard; G Milano
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.

Authors:  J S Waters; A Norman; D Cunningham; J H Scarffe; A Webb; P Harper; J K Joffe; M Mackean; J Mansi; M Leahy; A Hill; J Oates; S Rao; M Nicolson; T Hickish
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.

Authors:  T Leong; M Michael; K Foo; A Thompson; D Lim Joon; L Weih; S Ngan; R Thomas; J Zalcberg
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

10.  Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis.

Authors:  Sung Won Lee; Hae Lim Lee; Nam Ik Han; Jung Hyun Kwon; Soon Woo Nam; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon
Journal:  Ther Adv Med Oncol       Date:  2017-08-29       Impact factor: 8.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.